Skyline Dx, Janssen Partner on Companion Dx Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dutch array-based diagnostics firm Skyline Diagnostics today announced a deal with Janssen Pharmaceutica for the analysis of an undisclosed marketed compound.

Under the terms of the deal, Skyline will use its expertise and technologies in genetic profiling and bioinformatics to generate and analyze diagnostics information related to the compound from Janssen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.